Universität zu Köln

Vidal, Liat, Shpilberg, Ofer, Gurion, Ronit, Monsef, Ina, Raanani, Pia, Ram, Ron ORCID: 0000-0001-8683-6930 and Gafter-Gvili, Anat (2016). CHOP-like-14 compared to CHOP-like-21 for patients with aggressive lymphoma - a meta-analysis of randomized controlled trials. Acta Oncol., 55 (1). S. 77 - 85. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1651-226X

Full text not available from this repository.

Abstract

Background. R-CHOP-21 has remained the standard chemotherapy for aggressive non-Hodgkin's lymphoma. It was suggested that decreasing the treatment interval from three weeks (CHOP-21) to two weeks (CHOP-14) may improve survival and disease control of patients with aggressive lymphoma.Purpose. To evaluate the effect of CHOP-like-14 (with or without rituximab) compared to standard CHOP-like -21 on overall survival (OS), disease control and toxicity of patients with aggressive non-Hodgkin lymphoma.Methods. Systematic review and meta-analysis of RCTs. In October 2014 we searched The Cochrane Library, MEDLINE, LILACS, conference proceedings, and databases of ongoing trials. Authors were contacted for complementary data. The primary outcome was OS.Results. We identified seven trials (4073 patients), conducted between the years 1999 and 2008. Trials were at low or unclear risk for selection bias, and at low or unclear risk of attrition bias. CHOP-like-14 improved OS of patients with aggressive lymphoma compared to the same regimen given every 21 days (all trials): HR of death 0.86, 95% confidence interval (CI) 0.77-0.97. There was no OS difference between rituximab-CHOP-like 14 to rituximab-CHOP-like-21 (3 trials): HR 0.93 95% CI 0.78-1.10. The rates of progression or death, complete response, treatment-related mortality, grade 3-4 infection, and discontinuation were similar between groups.Conclusion. R-CHOP-21 remains the standard of care for patient with aggressive B-cell lymphoma. CHOP-14 can be considered as in case rituximab is omitted.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Vidal, Liat UNSPECIFIED UNSPECIFIED UNSPECIFIED Shpilberg, Ofer UNSPECIFIED UNSPECIFIED UNSPECIFIED Gurion, Ronit UNSPECIFIED UNSPECIFIED UNSPECIFIED Monsef, Ina UNSPECIFIED UNSPECIFIED UNSPECIFIED Raanani, Pia UNSPECIFIED UNSPECIFIED UNSPECIFIED Ram, Ron UNSPECIFIED orcid.org/0000-0001-8683-6930 UNSPECIFIED Gafter-Gvili, Anat UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-287725
DOI:	10.3109/0284186X.2015.1043025
Journal or Publication Title:	Acta Oncol.
Volume:	55
Number:	1
Page Range:	S. 77 - 85
Date:	2016
Publisher:	TAYLOR & FRANCIS LTD
Place of Publication:	ABINGDON
ISSN:	1651-226X
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language NON-HODGKINS-LYMPHOMA; B-CELL LYMPHOMA; CHEMOTHERAPY PLUS RITUXIMAB; 3-WEEKLY CHOP CHEMOTHERAPY; ELDERLY-PATIENTS; YOUNG-PATIENTS; BIWEEKLY CHOP; PHASE-II; STANDARD CHOP; SURVIVAL Multiple languages Oncology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/28772